T
here is essentially universal agreement that diabetes is associated with markedly increased risk of atherosclerotic cardiovascular disease (CVD). Moreover, most studies have indicated that this increased risk is not explained by raised levels of conventional cardiovascular risk factors, although admittedly this question has not been fully evaluated in prospective studies with respect to some of the newer cardiovascular risk factors such as small, dense LDL and plasminogen activator inhibitor-1 (PAI-1). Thus, scientists have speculated for a long time that some intrinsic feature of the diabetic state-perhaps the hyperglycemia itself-is responsible for the enhanced cardiovascular risk. This possibility has led to the further speculation that plasma glucose concentration might be a cardiovascular risk factor across its entire range, including, in particular, the euglycemic range. For many years, these two separate but interrelated questions were not clearly distinguished. Several developments over the past 20 years or so, however, have contributed to a sharper delineation of these issues.
The first development was the promulgation in 1979-1980 and the subsequent near-universal adoption of the National Diabetes Data Group (NDDG) and World Health Organization (WHO) criteria for diagnosing diabetes. These criteria have recently been revised, mainly by lowering the fasting plasma glucose cutpoint from 7.8 mmolA (140 mg/dl) to 7.0 mmol/1 (126 mg/dl) to make it more comparable in terms of sensitivity and specificity to the 2-h post-oral glucose load criterion of 11.1 mmol/1 (200 mg/dl), which has been retained (1) . Whatever the limitations of the original NDDG and WHO criteria, however, before their adoption, it was often difficult to decide whether various study populations did or did not include people with diabetes and, if they did, how many. With variable numbers of people with diabetes included in these populations, glucose levels could have been merely a proxy for the presence of diabetic subjects, whose cardiovascular risk was increased for reasons unrelated to glycemia per se. The second development was the recognition that glucose concentrations in many populations followed a bimodal distribution and, thus, that the cutpoint between euglycemia and diabetes was not purely arbitrary (2) . These findings reinforced the notion that glycemic level as a cardiovascular risk factor in the normal population and glycemic level as a cardiovascular risk factor in diabetic subjects constituted two separate questions. Finally, the explosion of knowledge about glycation of tissue proteins, circulating LDL, etc. provided a possible biological mechanism, heretofore missing, by which glycemia might contribute to atherogenesis.
This months issue of Diabetes Care provides a concise, yet remarkably comprehensive review of the evidence for and against glycemia as a cardiovascular risk factor (3). Quite appropriately, Dr. BarrettConnor has separated the discussion into studies of the general population, i.e., mainly nondiabetic subjects, and studies of diabetic patients. She concludes that in the former case, the evidence for glycemia as a cardiovascular risk factor is weak and inconsistent, but that in the latter case, it is more convincing. It has been said that the advent of glycohemoglobin measurements, which integrate average glycemic levels over many weeks rather than providing an instantaneous snapshot, has facilitated the documentation of glycemia as a cardiovascular risk factor in diabetic subjects. In fact, this result has been observed in a number of studies using ordinary glucose levels (4,5). Barrett-Connor notes that the evidence implicating glycemia as a cardiovascular risk factor in diabetic subjects cannot distinguish between glycemia itself and what she calls the "genetic burden" of diabetes. However, the presumably nonglycemic mechanisms whereby this genetic burden acts to enhance cardiovascular risk have not been spelled out. At least in the case of glycemia, plausible mechanisms involving glycation of various proteins have been postulated. Moreover, there could very well be a threshold for these effects such that they come into play only when the level of glycemia reaches diabetic or perhaps neardiabetic levels. Even studies such as the Whitehall Study (6) that are often cited as showing a relationship between glycemia and cardiovascular risk in nondiabetic subjects often show a threshold effect such that only those whose level of glycemia exceeds the 95th percentile (i.e., those very near to being diabetic) exhibit an increased cardiovascular risk.
On the other hand, Barrett-Connor rightly notes that there are as yet no satisfactory animal models of the glycemia-cardiovascular disease relationship and that ultimately only clinical trials can definitively resolve this issue. Moreover, such trials have the potential of laying to rest other nagging questions, namely those relating to the possible cardiotoxicity of sulfonylureas and the possible atherogenicity of insulin.
Note also that, although not strictly a clinical trial, the Epidemiology of Diabetes Interventions and Complications (EDIC) Study has the potential of shedding light on the glycemia-CVD association. This study is a posttrial follow-up of participants originally enrolled in the Diabetes Control and Complications Trial (DCCT), which, as noted in Barrett-Connors review, did not generate a sufficient number of cardiovascular events to provide a definitive answer with respect to this endpoint. If, however, during the average 6.5 years of participation in the trial itself, atherogenesis was sufficiently retarded among those intensively managed, the early, statistically nonsignificant deficit in cardiovascular events in this group might persist and eventually reach statistical significance. This would provide moderately convincing support for the hypothesis that glycemic control could reduce the incidence of CVD.
Finally, Barrett-Connor is undoubtedly correct to call for a balanced approach to treating cardiovascular risk factors in diabetic patients. Although aggressive glycemic control is undoubtedly indicated to retard the development of microvascular complications, and although such management may contribute to lowering cardiovascular risk as well, a single-minded pursuit of optimum glycemic control should not be allowed to obscure the need for vigorous management of established cardiovascular risk factors, notably hypertension and dyslipidemia, in diabetic patients. DIABETES CARE, VOLUME 20, NUMBER 10, OCTOBER 1997
